Tonix Pharmaceuticals Holding Corp. (TNXP)
$
42.02
+4.33 (10.30%)
Key metrics
Financial statements
Free cash flow per share
-10.1138
Market cap
276.1 Million
Price to sales ratio
27.4940
Debt to equity
0.0031
Current ratio
12.3146
Income quality
0.4508
Average inventory
8.3 Million
ROE
-1.0553
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and licensing of therapeutics and diagnostics aimed at treating and preventing human diseases while alleviating suffering. The company's diverse portfolio encompasses areas such as immunology, rare diseases, infectious diseases, and central nervous system (CNS) product candidates. Within its immunology portfolio, Tonix includes biologics designed to tackle organ transplant rejection, autoimmunity, and cancer, with notable candidates like TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, currently in development for the prevention of allograft and xenograft rejection, as well as for the treatment of autoimmune diseases. Furthermore, its rare disease portfolio features TNX-2900, which is aimed at treating Prader-Willi syndrome. The infectious disease pipeline encompasses TNX-801, a vaccine intended to prevent smallpox and monkeypox; TNX-1840 and TNX-1850, live virus vaccines derived from the recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug developed to manage acute COVID-19; and TNX-102 SL, targeting Long COVID, a chronic post-acute COVID-19 condition. Additionally, Tonix’s CNS portfolio includes various small molecules and biologics for pain, neurologic, psychiatric, and addiction treatment, featuring TNX-102 SL, currently in mid-Phase 3 trials for fibromyalgia management; TNX-1900, aimed at preventing migraine headaches; and TNX-1300, which is designed to address cocaine intoxication. Founded in 2007 and headquartered in Chatham, New Jersey, the company incurred an income tax expense of -$1,167,000.00 indicating its tax obligations. The total costs and expenses for the company are $87,838,000.00 reflecting its overall spending. The diluted EPS is -$3,504.00 accounting for potential share dilution. The company reported selling, general, and administrative expenses of $40,101,000.00 indicating its operational overhead costs, along with depreciation and amortization expenses of $3,421,000.00 which reflect the wear and tear of its assets. In the current market environment, the stock is affordable at $42.02 making it suitable for budget-conscious investors. Notably, the stock exhibits a high average trading volume of 1,516,356.00 indicating strong liquidity that may attract investors. With a market capitalization of $307,782,633.00 the company is categorized as a small-cap player. It holds a significant position in the Biotechnology industry, contributing meaningfully to the overall market landscape. Furthermore, the company belongs to the Healthcare sector, which is essential in driving innovation and fostering growth within the biopharmaceutical field.
Is Tonix Pharmaceuticals Holding Corp. (TNXP) a good investment?
Investing in Tonix Pharmaceuticals Holding Corp. (TNXP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Tonix Pharmaceuticals Holding Corp. (TNXP)'s stock forecast?
Analysts predict Tonix Pharmaceuticals Holding Corp. stock to fluctuate between $6.76 (low) and $544 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tonix Pharmaceuticals Holding Corp.'s market capitalization?
As of 2025-05-30, Tonix Pharmaceuticals Holding Corp.'s market cap is $307,782,633, based on 7,324,670 outstanding shares.
How does Tonix Pharmaceuticals Holding Corp. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Tonix Pharmaceuticals Holding Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tonix Pharmaceuticals Holding Corp. (TNXP) stock?
To buy Tonix Pharmaceuticals Holding Corp. (TNXP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TNXP. Place an order (Market, Limit, etc.).
What is the best time to invest in Tonix Pharmaceuticals Holding Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Tonix Pharmaceuticals Holding Corp. stock ever split?
Tonix Pharmaceuticals Holding Corp.'s last stock split was 1:100 on 2025-02-05.
How did Tonix Pharmaceuticals Holding Corp. perform in the last earnings report?
Revenue: $10,094,000 | EPS: -$3,504 | Growth: -44.98%.
Where can I find Tonix Pharmaceuticals Holding Corp.'s investor relations reports?
Visit https://www.tonixpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tonix Pharmaceuticals Holding Corp.?
You can explore historical data from here
What is the all-time high and low for Tonix Pharmaceuticals Holding Corp. stock?
All-time high: $1,356,800 (2021-02-11) | All-time low: $6.76 (2025-03-04).
What are the key trends affecting Tonix Pharmaceuticals Holding Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
9 days ago
CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase.
globenewswire.com
10 days ago
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD)
globenewswire.com
17 days ago
Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene
globenewswire.com
18 days ago
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years
globenewswire.com
a month ago
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells
globenewswire.com
a month ago
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an oral presentation at the World Vaccine Congress Washington 2025, held April 21-24, 2025, in Washington, D.C.
globenewswire.com
a month ago
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C.
globenewswire.com
2 months ago
Agreement includes the use of Tonix's TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana's genetically engineered pig organs in xenotransplantation
globenewswire.com
2 months ago
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia
globenewswire.com
2 months ago
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D.
See all news
